I det kliniske studie, Helsinki Heart Study, der er et stort placebo- kontrolleret studie med 4081 mandlige patienter i alderen 40- 55 år med primær dyslipidæmi (hovedsagelig forhøjet ikke- HDL kolesterol + / - hypertriglyceridæmi), men ingen tidligere koronar hjertesygdom i anamnesen, viste at behandling med 600 mg gemfibrozil 2 gange dagligt signifikant kunne reducere total plasmatriglycerider, total og LD - lipoprotein kolesterol og gav en signifikant stigning i HD- lipoprotein kolesterol.
In the Helsinki Heart Study, which was a large placebo-controlled study with 4081 male subjects, 40 to 55 years of age, with primary dyslipidaemia (predominantly raised non-HDL cholesterol +/ - hypertriglyceridaemia), but no previous history of coronary heart disease, gemfibrozil 600 mg twice daily, produced a significant reduction in total plasma triglycerides, total and low density lipoprotein cholesterol and a significant increase in high density lipoprotein cholesterol.